AAPL   331.50 (+2.85%)
MSFT   187.20 (+2.34%)
FB   230.77 (+1.98%)
GOOGL   1,440.02 (+1.82%)
AMZN   2,483.00 (+0.91%)
NVDA   356.80 (+1.75%)
CGC   16.51 (-0.72%)
BABA   219.55 (+0.69%)
MU   53.72 (+4.88%)
GE   7.88 (+1.81%)
TSLA   885.66 (+2.46%)
AMD   53.10 (+0.89%)
T   32.77 (+3.05%)
ACB   13.94 (-2.04%)
F   7.34 (+5.46%)
GILD   76.75 (-1.02%)
DIS   124.82 (+0.91%)
NFLX   419.60 (+1.27%)
BAC   28.11 (+4.97%)
BA   205.43 (+11.47%)
AAPL   331.50 (+2.85%)
MSFT   187.20 (+2.34%)
FB   230.77 (+1.98%)
GOOGL   1,440.02 (+1.82%)
AMZN   2,483.00 (+0.91%)
NVDA   356.80 (+1.75%)
CGC   16.51 (-0.72%)
BABA   219.55 (+0.69%)
MU   53.72 (+4.88%)
GE   7.88 (+1.81%)
TSLA   885.66 (+2.46%)
AMD   53.10 (+0.89%)
T   32.77 (+3.05%)
ACB   13.94 (-2.04%)
F   7.34 (+5.46%)
GILD   76.75 (-1.02%)
DIS   124.82 (+0.91%)
NFLX   419.60 (+1.27%)
BAC   28.11 (+4.97%)
BA   205.43 (+11.47%)
AAPL   331.50 (+2.85%)
MSFT   187.20 (+2.34%)
FB   230.77 (+1.98%)
GOOGL   1,440.02 (+1.82%)
AMZN   2,483.00 (+0.91%)
NVDA   356.80 (+1.75%)
CGC   16.51 (-0.72%)
BABA   219.55 (+0.69%)
MU   53.72 (+4.88%)
GE   7.88 (+1.81%)
TSLA   885.66 (+2.46%)
AMD   53.10 (+0.89%)
T   32.77 (+3.05%)
ACB   13.94 (-2.04%)
F   7.34 (+5.46%)
GILD   76.75 (-1.02%)
DIS   124.82 (+0.91%)
NFLX   419.60 (+1.27%)
BAC   28.11 (+4.97%)
BA   205.43 (+11.47%)
AAPL   331.50 (+2.85%)
MSFT   187.20 (+2.34%)
FB   230.77 (+1.98%)
GOOGL   1,440.02 (+1.82%)
AMZN   2,483.00 (+0.91%)
NVDA   356.80 (+1.75%)
CGC   16.51 (-0.72%)
BABA   219.55 (+0.69%)
MU   53.72 (+4.88%)
GE   7.88 (+1.81%)
TSLA   885.66 (+2.46%)
AMD   53.10 (+0.89%)
T   32.77 (+3.05%)
ACB   13.94 (-2.04%)
F   7.34 (+5.46%)
GILD   76.75 (-1.02%)
DIS   124.82 (+0.91%)
NFLX   419.60 (+1.27%)
BAC   28.11 (+4.97%)
BA   205.43 (+11.47%)
Log in

NASDAQ:MTEMMolecular Templates Stock Price, Forecast & News

$14.22
-0.73 (-4.88 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$14.09
Now: $14.22
$15.03
50-Day Range
$14.96
MA: $16.22
$17.63
52-Week Range
$4.51
Now: $14.22
$19.12
Volume318,429 shs
Average Volume306,725 shs
Market Capitalization$649.97 million
P/E RatioN/A
Dividend YieldN/A
Beta2.44
Molecular Templates, Inc., a clinical stage oncology company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed/refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. The company also develops MT-4019, engineered toxin body targeting CD38; and TAK-169 targeting CD38. It has an agreement with Takeda Pharmaceutical Company Limited to develop CD38-targeted engineered toxin bodies for the treatment of patients with diseases, such as multiple myeloma. Molecular Templates, Inc. is headquartered in Austin, Texas.
Read More
Molecular Templates logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.62 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:MTEM
CUSIP88580720
Phone512-869-1555

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.27 million
Book Value$2.79 per share

Profitability

Net Income$-69,420,000.00
Net Margins-439.48%

Miscellaneous

Employees68
Market Cap$649.97 million
Next Earnings Date8/10/2020 (Estimated)
OptionableNot Optionable

Receive MTEM News and Ratings via Email

Sign-up to receive the latest news and ratings for MTEM and its competitors with MarketBeat's FREE daily newsletter.

Molecular Templates (NASDAQ:MTEM) Frequently Asked Questions

How has Molecular Templates' stock been impacted by COVID-19 (Coronavirus)?

Molecular Templates' stock was trading at $13.22 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MTEM shares have increased by 7.6% and is now trading at $14.22. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Molecular Templates?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Molecular Templates in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Molecular Templates.

When is Molecular Templates' next earnings date?

Molecular Templates is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Molecular Templates.

How were Molecular Templates' earnings last quarter?

Molecular Templates Inc (NASDAQ:MTEM) posted its quarterly earnings data on Tuesday, May, 12th. The biotechnology company reported ($0.48) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by $0.18. The biotechnology company had revenue of $4.14 million for the quarter, compared to the consensus estimate of $10.48 million. Molecular Templates had a negative net margin of 439.48% and a negative return on equity of 76.76%. View Molecular Templates' earnings history.

When did Molecular Templates' stock split? How did Molecular Templates' stock split work?

Molecular Templates shares reverse split on the morning of Wednesday, August 2nd 2017. The 1-11 reverse split was announced on Tuesday, August 1st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 1st 2017. An investor that had 100 shares of Molecular Templates stock prior to the reverse split would have 9 shares after the split.

What price target have analysts set for MTEM?

4 brokers have issued 12-month price targets for Molecular Templates' stock. Their forecasts range from $19.00 to $22.00. On average, they expect Molecular Templates' stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 47.7% from the stock's current price. View analysts' price targets for Molecular Templates.

Has Molecular Templates been receiving favorable news coverage?

Media headlines about MTEM stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Molecular Templates earned a daily sentiment score of 0.7 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View the latest news aboutMolecular Templates.

Are investors shorting Molecular Templates?

Molecular Templates saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 1,470,000 shares, a drop of 13.5% from the April 15th total of 1,700,000 shares. Based on an average daily volume of 278,800 shares, the short-interest ratio is currently 5.3 days. Approximately 5.3% of the company's stock are sold short. View Molecular Templates' Current Options Chain.

Who are some of Molecular Templates' key competitors?

What other stocks do shareholders of Molecular Templates own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Molecular Templates investors own include ZIOPHARM Oncology (ZIOP), Novavax (NVAX), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP), TG Therapeutics (TGTX), CEL-SCI (CVM), SLS International (SLS), Amarin (AMRN), Corbus Pharmaceuticals (CRBP) and Exelixis (EXEL).

Who are Molecular Templates' key executives?

Molecular Templates' management team includes the following people:
  • Dr. Eric E. Poma, CEO, Chief Scientific Officer & Director (Age 47)
  • Ms. Jason S Kim, Pres & COO (Age 44)
  • Mr. Adam D. Cutler B.A., Chief Financial Officer (Age 44)
  • Mr. Kurt Elster, Exec. VP of Corp. Devel. (Age 52)
  • Dr. Jack Higgins Ph.D., Exec. VP of Operations & Head of Manufacturing (Age 39)

What is Molecular Templates' stock symbol?

Molecular Templates trades on the NASDAQ under the ticker symbol "MTEM."

Who are Molecular Templates' major shareholders?

Molecular Templates' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (5.35%), Geode Capital Management LLC (0.77%), Telemark Asset Management LLC (0.77%), State Street Corp (0.71%), Monashee Investment Management LLC (0.40%) and Nuveen Asset Management LLC (0.26%). Company insiders that own Molecular Templates stock include Associates LLC Cdk, David Hirsch, Kevin M Lalande, Longitude Capital Partners Iii and Scott D Morenstein. View institutional ownership trends for Molecular Templates.

Which major investors are selling Molecular Templates stock?

MTEM stock was sold by a variety of institutional investors in the last quarter, including Monashee Investment Management LLC, Two Sigma Investments LP, Morgan Stanley, Mackenzie Financial Corp, Invesco Ltd., UBS Group AG, Russell Investments Group Ltd., and Strs Ohio. View insider buying and selling activity for Molecular Templates.

Which major investors are buying Molecular Templates stock?

MTEM stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Telemark Asset Management LLC, Deutsche Bank AG, JPMorgan Chase & Co., Hancock Whitney Corp, Geode Capital Management LLC, State Street Corp, and Nuveen Asset Management LLC. Company insiders that have bought Molecular Templates stock in the last two years include Associates LLC Cdk, David Hirsch, Longitude Capital Partners Iii, and Scott D Morenstein. View insider buying and selling activity for Molecular Templates.

How do I buy shares of Molecular Templates?

Shares of MTEM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Molecular Templates' stock price today?

One share of MTEM stock can currently be purchased for approximately $14.22.

How big of a company is Molecular Templates?

Molecular Templates has a market capitalization of $649.97 million and generates $22.27 million in revenue each year. The biotechnology company earns $-69,420,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Molecular Templates employs 68 workers across the globe.

What is Molecular Templates' official website?

The official website for Molecular Templates is www.mtem.com.

How can I contact Molecular Templates?

Molecular Templates' mailing address is 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729. The biotechnology company can be reached via phone at 512-869-1555 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.